Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 4801-4809

  Watanabe, Rei ^a,b   Ishiura, Nobuko ^a,b   Nakashima, Hiroko ^a,b   Kuwano, Yoshihiro ^b   Okochi, Hitoshi ^b   Tamaki, Kunihiko ^a   Sato, Shinichi ^a   Tedder, Thomas F ^d   Fujimoto, Manabu ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENYL KEYHOLE LIMPET HEMOCYANIN; ANTINUCLEAR ANTIBODY; CD19 ANTIGEN; CD1D ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; DNP KLH; INTERLEUKIN 10; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SPECIFICITY; CELL SURFACE; CELL TRANSFER; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DONOR SELECTION; FEMALE; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOPATHOGENESIS; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MOUSE; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; REGULATORY B CELL; SIGNAL TRANSDUCTION; SPLEEN; SURVIVAL RATE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; METABOLISM; MOUSE MUTANT; NEW ZEALAND BLACK MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD19; B-LYMPHOCYTE SUBSETS; DISEASE PROGRESSION; FEMALE; IMMUNOSUPPRESSION; LUPUS NEPHRITIS; LYMPHOPENIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; MICE, KNOCKOUT;

EID: 77954505663     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902385     Document Type: Article

References (72)

1. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N. Engl. J. Med. 358: 929-939.
2. Chan, O. T., M. P. Madaio, and M. J. Shlomchik. 1999. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169: 107-121.
3. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
4. Anolik, J. H. 2007. B cell biology and dysfunction in SLE. Bull. NYU Hosp. Jt. Dis. 65: 182-186.
5. Eisenberg, R., and D. Albert. 2006. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 20-27.
6. Dörner, T., and P. E. Lipsky. 2007. B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin. Biol. Ther. 7: 1287-1299.
7. Ramos-Casals, M., M. J. Soto, M. J. Cuadrado, and M. A. Khamashta. 2009. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 18: 767-776.
8. John Looney, R., J. Anolik, and I. Sanz. 2009. A perspective on B-cell-targeting therapy for SLE. Mod. Rheumatol. 20: 1-10.
9. Kurosaki, T. 2002. Regulation of B cell fates by BCR signaling components. Curr. Opin. Immunol. 14: 341-347.
10. Tedder, T. F. 1998. Introduction: response-regulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction. Semin. Immunol. 10: 259-265.
11. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256: 105-107.
12. 2+ mobilization. J. Exp. Med. 186: 1897-1910.
13. Fujimoto, M., A. P. Bradney, J. C. Poe, D. A. Steeber, and T. F. Tedder. 1999. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 11: 191-200. (Pubitemid 29428812)
14. Fujimoto, M., J. C. Poe, P. J. Jansen, S. Sato, and T. F. Tedder. 1999. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J. Immunol. 162: 7088-7094. (Pubitemid 29277677)
15. Fujimoto, M., Y. Fujimoto, J. C. Poe, P. J. Jansen, C. A. Lowell, A. L. DeFranco, and T. F. Tedder. 2000. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
16. Fearon, D. T., and M. C. Carroll. 2000. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18: 393-422.
17. Carter, R. H., and R. A. Barrington. 2004. Signaling by the CD19/CD21 complex on B cells. Curr. Dir. Autoimmun. 7: 4-32.
18. Del Nagro, C. J., D. C. Otero, A. N. Anzelon, S. A. Omori, R. V. Kolla, and R. C. Rickert. 2005. CD19 function in central and peripheral B-cell development. Immunol. Res. 31: 119-131.
19. Tedder, T. F., J. C. Poe, M. Fujimoto, K. M. Haas, and S. Sato. 2005. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr. Dir. Autoimmun. 8: 55-90.
20. Rickert, R. C., K. Rajewsky, and J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376: 352-355.
21. Engel, P., L. J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
22. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, and T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157: 4371-4378. (Pubitemid 126449355)
23. Inaoki, M., S. Sato, B. C. Weintraub, C. C. Goodnow, and T. F. Tedder. 1997. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J. Exp. Med. 186: 1923-1931.
24. Fujimoto, M., and S. Sato. 2007. B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. J. Dermatol. Sci. 46: 1-9.
25. Theofilopoulos, A. N., and F. J. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37: 269-390.
26. Wither, J. E., V. Roy, and L. A. Brennan. 2000. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice. Clin. Immunol. 94: 51-63.
27. Shirai, T., S. Hirose, T. Okada, and H. Nishimura. 1991. CD5+ B cells in autoimmune disease and lymphoid malignancy. Clin. Immunol. Immunopathol. 59: 173-186.
28. Hayakawa, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 157: 202-218.
29. Atencio, S., H. Amano, S. Izui, and B. L. Kotzin. 2004. Separation of the New Zealand Black genetic contribution to lupus from New Zealand Black determined expansions of marginal zone B and B1a cells. J. Immunol. 172: 4159-4166. (Pubitemid 38375228)
30. Mizoguchi, A., and A. K. Bhan. 2006. A case for regulatory B cells. J. Immunol. 176: 705-710.
31. Mauri, C., and M. R. Ehrenstein. 2008. The 'short' history of regulatory B cells. Trends Immunol. 29: 34-40.
32. Bouaziz, J. D., K. Yanaba, and T. F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
33. Fillatreau, S., D. Gray, and S. M. Anderton. 2008. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8: 391-397.
34. + phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
35. Wolf, S. D., B. N. Dittel, F. Hardardottir, and C. A. Janeway, Jr. 1996. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184: 2271-2278.
36. Mizoguchi, A., E. Mizoguchi, R. N. Smith, F. I. Preffer, and A. K. Bhan. 1997. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J. Exp. Med. 186: 1749-1756.
37. Mizoguchi, A., E. Mizoguchi, H. Takedatsu, R. S. Blumberg, and A. K. Bhan. 2002. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219-230.
38. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
39. Mauri, C., D. Gray, N. Mushtaq, and M. Londei. 2003. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197: 489-501.
40. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
41. Watanabe, R., M. Fujimoto, N. Ishiura, Y. Kuwano, H. Nakashima, N. Yazawa, H. Okochi, S. Sato, T. F. Tedder, and K. Tamaki. 2007. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am. J. Pathol. 171: 560-570.
42. Matsushita, T., M. Fujimoto, M. Hasegawa, K. Komura, K. Takehara, T. F. Tedder, and S. Sato. 2006. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol. 168: 812-821.
43. Passwell, J., G. F. Schreiner, M. Nonaka, H. U. Beuscher, and H. R. Colten. 1988. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J. Clin. Invest. 82: 1676-1684.
44. van Zelm, M. C., I. Reisli, M. van der Burg, D. Castaño, C. J. van Noesel, M. J. van Tol, C. Woellner, B. Grimbacher, P. J. Patiño, J. J. van Dongen, and J. L. Franco. 2006. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354: 1901-1912.
45. Moutsopoulos, H. M., M. Boehm-Truitt, S. S. Kassan, and T. M. Chused. 1977. Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J. Immunol. 119: 1639-1644.
46. Cohen, P. L., and M. Ziff. 1977. Abnormal polyclonal B cell activation in NZB/NZW F1 mice. J. Immunol. 119: 1534-1537.
47. Izui, S., P. J. McConahey, and F. J. Dixon. 1978. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J. Immunol. 121: 2213-2219.
48. Klinman, D. M. 1990. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J. Clin. Invest. 86: 1249-1254.
49. Fujimoto, M., J. C. Poe, A. B. Satterthwaite, M. I. Wahl, O. N. Witte, and T. F. Tedder. 2002. Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction. J. Immunol. 168: 5465-5476.
50. Buhl, A. M., and J. C. Cambier. 1999. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. J. Immunol. 162: 4438-4446.
51. Yanaba, K., J. D. Bouaziz, T. Matsushita, T. Tsubata, and T. F. Tedder. 2009. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182: 7459-7472.
52. Abe, J., S. Ueha, J. Suzuki, Y. Tokano, K. Matsushima, and S. Ishikawa. 2008. Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am. J. Pathol. 173: 1682-1692.
53. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
54. Haas, K. M., R. Watanabe, T. Matsushita, H. Nakashima, N. Ishiura, H. Okochi, M. Fujimoto, and T. F. Tedder. 2010. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J. Immunol. 184: 4789-4800.
55. Shi, X., C. Xie, S. Chang, X. J. Zhou, T. Tedder, and C. Mohan. 2007. CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 56: 3057-3069.
56. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639-1648.
57. Waters, S. T., M. McDuffie, H. Bagavant, U. S. Deshmukh, F. Gaskin, C. Jiang, K. S. Tung, and S. M. Fu. 2004. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 199: 255-264.
58. Christensen, S. R., M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202: 321-331.
59. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226: 205-218.
60. Houssiau, F. A., C. Lefebvre, M. Vanden Berghe, M. Lambert, J. P. Devogelaer, and J. C. Renauld. 1995. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393-395.
61. Llorente, L., W. Zou, Y. Levy, Y. Richaud-Patin, J. Wijdenes, J. Alcocer-Varela, B. Morel-Fourrier, J. C. Brouet, D. Alarcon-Segovia, P. Galanaud, and D. Emilie. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181: 839-844.
62. Hagiwara, E., M. F. Gourley, S. Lee, and D. K. Klinman. 1996. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum. 39: 379-385.
63. Liu, T. F., and B. M. Jones. 1998. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 10: 140-147.
64. González-Amaro, R., D. Portales-Pérez, L. Baranda, C. Abud-Mendoza, L. Llorente, Y. Richaud-Patin, J. Alcocer-Varela, and D. Alarcón-Segovia. 1998. Role of IL-10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus. J. Autoimmun. 11: 395-402.
65. Gröndal, G., I. Gunnarsson, J. Rönnelid, S. Rogberg, L. Klareskog, and I. Lundberg. 2000. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 18: 565-570.
66. Chun, H. Y., J. W. Chung, H. A. Kim, J. M. Yun, J. Y. Jeon, Y. M. Ye, S. H. Kim, H. S. Park, and C. H. Suh. 2007. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27: 461-466.
67. Yin, Z., G. Bahtiyar, N. Zhang, L. Liu, P. Zhu, M. E. Robert, J. McNiff, M. P. Madaio, and J. Craft. 2002. IL-10 regulates murine lupus. J. Immunol. 169: 2148-2155.
68. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179: 305-310.
69. Martin, F., and A. C. Chan. 2006. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24: 467-496.
70. Chan, O., and M. J. Shlomchik. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160: 51-59.
71. Li, Y., F. Chen, M. Putt, Y. K. Koo, M. Madaio, J. C. Cambier, P. L. Cohen, and R. A. Eisenberg. 2008. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181: 2961-2972.
72. Martin, F., and A. C. Chan. 2004. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20: 517-527.